{"article_title": "Health care leads S&P as St. Jude gets some good news from FDA", "article_keywords": ["fda", "pharmacyclics", "recent", "good", "twitter", "sp", "jude", "st", "leads", "released", "high", "health", "nearly", "shares", "device", "gets", "care"], "article_url": "http://blogs.marketwatch.com/health-exchange/2013/10/04/health-care-leads-sp-as-st-jude-gets-some-good-news-from-fda/", "article_text": "It\u2019s Day 4 of Obamacare, and health stocks are basking in its glory, as House Speaker John Boehner reportedly has indicated he would not hold the nation\u2019s debt ceiling as a bargaining chip to defund the Affordable Care Act.\n\nThe sector was far outpacing the rest of the market among S&P 500 companies in early trading Friday, up nearly 0.9%.\n\nSt. Jude Medical\n\nAt the top of the class was medical device maker St. Jude Medical Inc. /quotes/zigman/242119 /quotes/nls/stj STJ , up nearly 4% to $56.80 in recent action. Privately held CardioMEMS, of which St. Jude has a 19% stake, has received positive indications from the U.S. Food and Drug Administration of approval for a heart-failure detection device, according to a research report from Leerink Swann analyst Danielle Antalffy.\n\nAntalffy said the FDA released documents ahead of meeting next Wednesday in which the FDA acknowledged its effectiveness, and she now puts the likelihood of approval of the device at 90%. She also points out that St. Jude has exclusive rights to buy CardioMEMS for $375 million.\n\nAlso near the top was Dentsply International Inc. /quotes/zigman/54261 /quotes/nls/xray XRAY , of all companies. Reports were being released outlining the global prospects for dental suppliers, like Dentsply, already a big worldwide player in its sector.\n\nDentsply shares were up more than 3% to $44.71 in recent action, and was nearing the 52-week high reached on Sept. 11.\n\nIn the pharmaceutical group, Pharmacyclics Inc. /quotes/zigman/53242 /quotes/nls/pcyc PCYC continued its meteoric rise, up nearly 5% to a new all-time high of $142.28 after Wells Fargo analyst Matthew Andrews initiated coverage of the maker of the blood-cancer treatment ibrutinib, and rated it \u201coutperform.\u201d\n\n\u201cWhile consensus expectations are high for ibrutinib\u2019s launch and [Pharmacyclic's] shares have appreciated about 130% in 2013 versus the [NYSE Arca Biotechnology Index's] 40%, long term we see [Pharmacyclic] as undervalued, due to ibrutinib\u2019s opportunities in multiple blood cancers,\u201d Andrews said in a note to clients.\n\nFollow Russ Britt on Twitter @russbrittmktw\n\nFollow Health Exchange on Twitter @MWHealthBlog", "article_metadata": {"article.created": "2013-10-04T11:49:56-04:00", "application-name": "MarketWatch.com", "twitter": {"domain": "Marketwatch.com", "description": "On Day 4 of Obamacare, health stocks are basking in its glory, as House Speaker John Boehner indicates he would not hold the nation's debt ceiling as a bargaining chip to defund the Affordable Care Act.", "title": "Health care leads S&P as St. Jude gets some good news from FDA", "url": "http://blogs.marketwatch.com/health-exchange/2013/10/04/health-care-leads-sp-as-st-jude-gets-some-good-news-from-fda/", "image": {"src": "http://s.wsj.net/public/resources/MWimages/MW-BM509_logo_s_MG_20131004110109.jpg"}, "site": "MarketWatch", "card": "summary_large_image"}, "article.author": "Russ Britt", "article.section": "Markets", "keywords": "Biopharmaceuticals,Dentsply International Inc.,health care,Medical suppliers,Obamacare,Pharmacyclics Inc.,St. Jude Medical", "article.headline": "Health care leads S&P as St. Jude gets some good news from FDA", "msapplication-task": "name=SmartMoney;action-uri=http://www.smartmoney.com/;icon-uri=http://www.smartmoney.com/favicon.ico", "news_keywords": "Biopharmaceuticals,Dentsply International Inc.,health care,Medical suppliers,Obamacare,Pharmacyclics Inc.,St. Jude Medical", "author": "Russ Britt", "article.page": "Health Exchange Blog", "description": "On Day 4 of Obamacare, health stocks are basking in its glory, as House Speaker John Boehner indicates he would not hold the nation's debt ceiling as a bargaining chip to defund the Affordable Care Act.", "article.published": "2013-10-04T11:49:56-04:00", "ROBOTS": "noarchive, noodp", "msapplication-tooltip": "MarketWatch", "fb": {"url": "http://blogs.marketwatch.com/health-exchange/2013/10/04/health-care-leads-sp-as-st-jude-gets-some-good-news-from-fda/", "app_id": 283204329838}, "article": {"publisher": "https://www.facebook.com/marketwatch", "image_count": 2}, "og": {"site_name": "Marketwatch", "description": "On Day 4 of Obamacare, health stocks are basking in its glory, as House Speaker John Boehner indicates he would not hold the nation's debt ceiling as a bargaining chip to defund the Affordable Care Act.", "title": "Health care leads S&P as St. Jude gets some good news from FDA", "url": "http://blogs.marketwatch.com/health-exchange/2013/10/04/health-care-leads-sp-as-st-jude-gets-some-good-news-from-fda/", "image": {"width": 569, "identifier": "http://s.wsj.net/public/resources/MWimages/MW-BM509_logo_s_MG_20131004110109.jpg", "height": 398}, "type": "article"}, "article.access": "free", "article.type": "Health Exchange", "article.id": "BL-MW243B-1278", "article.updated": "2013-10-04T11:49:56-04:00"}, "article_summary": "St. Jude MedicalAt the top of the class was medical device maker St. Jude Medical Inc. /quotes/zigman/242119 /quotes/nls/stj STJ , up nearly 4% to $56.80 in recent action.\nShe also points out that St. Jude has exclusive rights to buy CardioMEMS for $375 million.\nThe sector was far outpacing the rest of the market among S&P 500 companies in early trading Friday, up nearly 0.9%.\nFollow Russ Britt on Twitter @russbrittmktwFollow Health Exchange on Twitter @MWHealthBlog\nDentsply shares were up more than 3% to $44.71 in recent action, and was nearing the 52-week high reached on Sept. 11."}